

Maryland Board of Pharmacy  
**Public Board Meeting**

**Agenda**  
**Date: June 19, 2013**

<b>Name</b>	<b>Title</b>	<b>Present</b>	<b>Absent</b>	<b>Present</b>	<b>Absent</b>
<b>Board Committee</b>					
Bradley-Baker, L.	Commissioner/Treasurer				
Chason, D.	Commissioner				
Finke, H.	Commissioner				
Gavgani, M. Z.	Commissioner				
Israbian-Jamgochian, L.	Commissioner				
Jones, David H.	Commissioner				
Matens, R.	Commissioner				
Smith, J.	Commissioner				
Souranis, M.	Commissioner/President				
St. Cyr, II, Z. W.	Commissioner				
Taylor, R.	Commissioner/Secretary				
<b>Board Counsel</b>					
Bethman, L.	Board Counsel				
Felter, B.	Staff Attorney				
<b>Board Staff</b>					
Naesea, L.	Executive Director				
Wu, Y.	Compliance Manager				
Waddell, L.	Licensing Manager				
Gaither, P.	Administration and Public Support Manager				
Jeffers, A.	Legislation/Regulations Manager				
Johnson, John	MIS Manager				

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
<b>I. Executive Committee Report(s)</b>	<b>A.) M. Souranis, Board President</b>  <b>B.) R. Taylor, Secretary</b>	<p><i>Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.</i></p> <ol style="list-style-type: none"> <li><b>1. Call to Order</b></li> <li><b>2. Sign-in Introduction and of meeting attendees –</b> <i>(Please indicate on sign-in sheet if you are requesting CE Units for attendance)</i></li> <li><b>3. Distribution of packet materials</b></li> <li><b>4. Review and approve May 15, 2013 Minutes</b> <b><u>Draft Public Minutes 5-17-2013</u></b></li> </ol>	
<b>II. A. Executive Director Report</b>	<b>L. Naesea, Executive Director</b>	<ol style="list-style-type: none"> <li><b>1. Operations Updates</b></li> <li><b>2. Meeting Updates</b></li> </ol>	
<b>B. Administration and Public Support (APS)</b>	<b>B. P. Gaither, APS Manager</b>	<ol style="list-style-type: none"> <li><b>1. Personnel Updates - Vacancies and Recruits</b></li> <li><b>2. Contracts and Procurement</b></li> </ol>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
C. MIS	J. Johnson, MIS Manager	1. MIS Update	
D. Licensing	L. Waddell, Licensing Manager	1. Licensing Unit Update 2. Monthly Statistics	
E. Compliance	Y. Wu, Compliance Manager	1. Monthly Statistics 2. PEAC Update	
F. Legislation & Regulations	A. Jeffers, Legislation & Regulations Manager	<p><b><u>REGULATIONS:</u></b></p> <p><b>10.34.03 – Inpatient Institutional Pharmacies</b> Anticipated to be published June 28, 2013.</p> <p><b>10.34.14 – Opening and Closing of Pharmacies and 10.34.30 – Change to Permit – Pharmacy or Distribution Permit Holder.</b> Notice of Final Action anticipated to be published either June 28<sup>th</sup> or July 12<sup>th</sup>.with effective date 10 days later.</p> <p><b>10.34.19 Sterile Pharmaceutical Compounding (Emergency)</b> Board approved revisions at May 15, 2013 Board Meeting. Revised proposal sent to the Secretary for initial comment May 23, 2013.</p> <p><b>Secretary Joshua Sharfstein, Department of Health and Mental Hygiene</b></p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<p><b>Maryland Veterinary Medical Association inquiry</b></p> <p><b><u>Veterinarian Office Use Compounding</u></b></p> <p><b>10.34.22 – Licensing of Wholesale Prescription Drug or Device Distributors (Emergency)</b>  Published April 19, 2013. 30 day comment period to follow.  Emergency was withdrawn on April 25, 2013. AELR putting this proposal on hold so it will not become effective until SB 595 becomes effective on October 1, 2013.</p> <p>Practice Committee to consider the revised proposal and comment received regarding the April 19<sup>th</sup> proposal.  <b>Board approval requested</b> for the “Reporting Form” for pharmacies that wholesale distribute to wholesale distributors:</p> <p><b><u>DRAFT Board of Pharm Reporting Form 060513ln</u></b></p> <p><b>10.34.23 Pharmaceutical Services to Patients in Comprehensive Care Facilities</b>  Published May 31, 2013. 30 day comment period to follow.  Comments to be considered at July 24<sup>th</sup> Practice Committee Meeting.</p> <p><b>10.34.32 Pharmacist Administration of Vaccinations</b>  Draft revisions to be considered at June 26<sup>th</sup> Practice Committee Meeting. Infectious Disease Unit working on criteria for the protocol.</p> <p><b>10.34.33 Prescription Drug Repository Program</b>  Proposal submitted May 22, 2013. In the DHMH sign-off process.</p> <p><b>10.13.01 Dispensing of Prescription Drugs by a Licensee</b></p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<p>Mike Souranis, Rodney Taylor, Lenna Israbian-Jamgochian, Harry Finke, LaVerne Naesea, Anna Jeffers, and Justin Ortique (pharmacy school student) met with Dr. Laura Herrera on June 5, 2013 to discuss her comments and the fiscal impact of inspections. Dr. Herrera plans to follow-up with the Board within 2 months.</p> <p><b><u>Dr. Laura Herrera June 13, 2013 Letter</u></b></p> <p><b><u>LEGISLATION:</u></b></p> <p><b><u>Naturopath Meetings organized by Board of Physicians - First meeting is tentatively June 27<sup>th</sup> and then on Tuesdays.</u></b></p> <p><b><u>Proposal ideas for 2014.</u></b></p> <p><b><u>Other Matters</u></b>  <b>Board comment requested for US HB 1919</b></p> <p><b><u>Email about OGA comment request on US HB1919</u></b></p> <p><b><u>Pharmaceutical paper inserts Gov Legislative Week June 3 2013 -- This Week on the House Floor (1)</u></b></p> <p><b><u>Pharmaceutical paper inserts Gov W ENGEL</u></b></p>	
<b>III. Committee Reports</b> <b>A. Practice Committee</b>	<b>H. Finke, Chair,</b>	<b>Inquiries:</b>  1) Sam Georgiou, Professional Arts Pharmacy	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<p><u>Non sterile Compounding</u></p> <p><u>Compounded office use products</u></p> <p><u>Draft Bd Response - compounding for office use</u></p> <p>2) Kathy Wille, C2R Global Manufacturing Inc. - Producer of "Drug Buster"</p> <p><u>Drug Buster</u></p> <p><u>Another Drug Buster inquiry</u></p> <p><u>Article with Inventor of the Drug Buster</u></p> <p><u>DEA-316 UPDATED ChemicalDrugDestruction</u></p> <p><u>Drug Buster description, claims and research</u></p> <p><u>Drug Buster DEA patent</u></p> <p><u>Fwd DEA 316</u></p> <p><u>msds drug buster RevA</u></p> <p><u>Draft Bd Response - Drug Buster</u></p> <p>3) Eric Hartkopf, PAAS National</p> <p><u>LTC - signatures on orders</u></p> <p><u>Draft Bd Response - LTC - signing dr orders</u></p> <p>4) Chandra Mouli, DDC</p> <p><u>DDC - approval of non pharmacy sites</u></p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		<b><u>Draft Bd Response – approval of non pharmacy sites</u></b>	
<b>B. Licensing Committee</b>	<b>D. Chason Chair,</b>	<b>1. New Business:</b> <ul style="list-style-type: none"> <li><b><u>CSM-Clinical Supplies Management</u></b> - Licensing Committee recommendation is to inform CSM that under MD law, medications must be sent directly to patients and be patient specific. The pharmacy has to be MD licensed and has to have at least one MD licensed pharmacist on staff.</li> </ul>	
<b>C. Public Relations Committee</b>	<b>L. Bradley-Baker, Chair</b>	<b>Public Relations Committee Update:</b> <ul style="list-style-type: none"> <li>Community outreach update; and</li> <li>Annual Board of Pharmacy CE Breakfast topic.</li> </ul>	
<b>D. Disciplinary</b>	<b>L. Israbian-Jamgochian Chair</b>	<b>Disciplinary Committee Update.</b>	
<b>E. Emergency Preparedness Task Force</b>	<b>L. Bradley-Baker, Acting Chair</b>	<b>Emergency Preparedness Task Force Update:</b> <ul style="list-style-type: none"> <li>Local health departments presentation; and</li> <li>Emergency Preparedness Exercise at UMES School of Pharmacy.</li> </ul>	
<b>IV. Other Business &amp; FYI</b>	<b>M. Souranis, Board</b>	<b>None</b>	

<b>Subject</b>	<b>Responsible Party</b>	<b>Discussion</b>	<b>Action Due Date (Assigned To)</b>
	<b>President</b>		
<b>V. Adjournment</b>	<b>M. Souranis, Board President</b>	<p>The Public Meeting was adjourned at _____.</p> <p>At _____ P.M. M. Souranis convened a Closed Public Session to conduct a medical review of technician applications.</p> <p>C. The Closed Public Session was adjourned at _____ P.M. Immediately thereafter, M. Souranis convened an Administrative Session for purposes of discussing confidential disciplinary cases. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Administrative Session.</p>	